Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs) EQUITY
$119.52
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | JNJ Avg Daily Volume: 6,936,800
Last Update: 02/22/17 - 4:01 PM EST
Volume: 0
YTD Performance: 3.74%
Open: $0.00
Previous Close: $119.52
52 Week Range: $102.97 - $126.07
Oustanding Shares: 2,720,531,728
Market Cap: 325,538,826,572
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 7 8 8
Moderate Buy 2 2 2 2
Hold 10 9 8 8
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.37 2.26 2.16 2.16
Latest Dividend: 0.80
Latest Dividend Yield: 2.67%
Dividend Ex-Date: 02/24/17
Price Earnings Ratio: 20.18
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
20.18 20.20 30.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.01% 14.10% 30.59%
GROWTH 12 Mo 3 Yr CAGR
Revenue -5.70 0.00 0.00
Net Income 7.30 0.20 0.06
EPS 8.30 0.20 0.07
Earnings for JNJ:
EBITDA 21.17B
Revenue 71.89B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $1.76 $1.80 $7.02 $7.43
Number of Analysts 8 7 10 10
High Estimate $1.80 $1.83 $7.14 $7.84
Low Estimate $1.71 $1.75 $6.95 $7.22
Prior Year $1.68 $1.74 $6.73 $7.02
Growth Rate (Year over Year) 4.84% 3.69% 4.35% 5.75%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Jim Cramer

 | Feb 22, 2017 | 11:45 AM EST
Icahn may have a tough time finding interest in this behemoth.
RMPIA
By

Doug Kass

 | Feb 21, 2017 | 2:55 PM EST
 
RMPIA
By

Bruce Kamich

 | Feb 16, 2017 | 11:18 AM EST
You might want to review your holdings in the sector.
RMPIA
By

Bret Jensen

 | Feb 15, 2017 | 11:30 AM EST
M&A activity is in a serious upswing, and here are some names to watch.
RMPIA
By

Jim Cramer

 | Feb 10, 2017 | 2:30 PM EST
Amazon, J&J, IBM and others don't deserve this treatment.
RMPIA
By

Jim Cramer

 | Feb 9, 2017 | 2:48 PM EST
They have become a referendum on Trump's plans for lower corporate taxes.
RMPIA
By

Bret Jensen

 | Jan 30, 2017 | 10:00 AM EST
M&A, drug approvals and Trump are all on my watch list.
By

Bret Jensen

 | Jan 29, 2017 | 2:00 PM EST
The Actelion buyout opens the way for other deals.
By

Bret Jensen

 | Jan 27, 2017 | 11:00 AM EST
The Actelion buyout opens the way for other deals.
RMPIA
By

Doug Kass

 | Jan 26, 2017 | 4:08 PM EST
The U.S. Dollar strengthened. The price of crude oil rose by over one dollar to $53.78/barrel. Gold fell by -$8.60 to $1189. Ag commodities: wheat +2.50, corn -2.50, soybean -7 and oats -5.5. Lumber increased by $1.50. Bonds rallied in price after an early morning spill. Yields dropped by two basis points. The yield curve was flat. Municipal bonds were flat, as were closed end muni bond funds. Junk was unchanged, Blackstone/GSO Strategic Credit Fund (BGB)  down $0.03. Banks prospered, though Citigroup (C) was lower. Insurance was mixed after a Metlife (MET) downgrade. Brokerages solid, led by GS (short and on Best Ideas List). Big pharma continues out of favor after large downside at Bristol-Myers (BMY) . Johnson & Johnson (JNJ) continues weak, after M&A announcement. Retail continues to underperform and the possible 20% tariff from Mexico (that Sean Spicer just mentioned) won't help. Nor will the possibility of a Sears (SHLD) bankruptcy (plenty of discounted merchandise could cause some indigestion over the next few months. Old media was mixed, awaiting Microsoft (MSFT) EPS this afternoon. Biotech continued its fade led by Allergan (AGN) , Celgene (CELG) and Gilead Sciences (GILD) . Speculative biotech also got hit. Consumer staples faltered despite the currency weakness. Campbell Soup (CPB) and Procter &
Here is a well defined zone to look for buy triggers against...defining the risk below it!...
this is the FOURTH big winner we have booked on Apple since December. SOLD AAPL APR 1...
Garmin is the top gainer in the S&P 500 today following this morning's...
Shares of Exxon Mobil  (XOM) have been declining steadily this year, and moved back d...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.